

**EudraCT number:** 2019-003449-14

**Sponsors:** Genentech Inc.

**Study Title:** A Phase II, Open-label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Patients Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-small Cell Lung Cancer

Although study GO41836 was planned to be conducted in Germany, Spain and the United Kingdom, the study was terminated early prior to patient enrollment due to feasibility challenges exacerbated by the pandemic. Since no patients were enrolled, study results will not be submitted.